Virus infection and human cancer An overview -- Epidemiology of virus infection and human cancer -- Viral oncogenes and human cancer -- Virus infection, inflammation and cancer prevention -- The oncogenic role of hepatitis B virus -- Prevention of hepatitis B virus infection and liver cancer -- The oncogenic role of hepatitis C virus -- Prevention of hepatitis C virus infection and liver cancer -- The oncogenic role of Human Papilloma virus -- Prevention of Human Papilloma virus and related cancers -- The oncogenic role of Epstein-Barr virus -- Prevention of Epstein-Barr virus infection and related cancers.- The oncogenic role of Human T-Cell Lymphotropic virus -- Prevention of Human T-Cell Lymphotropic virus infection and adult T-Cell leukemia -- The oncogenic role of Kaposi sarcoma-associated herpes virus (HHV-8).- Prevention of Kaposi sarcoma-associated herpes virus (HHV-8) and Kaposi s sarcoma.- Merkel cell polyomavirus (MCV) and human Merkel cell carcinoma.- Infection-associated cancer after transplantation Prevention and cure.- Viral infection and cancer prevention Future prospects
0
Research on oncogenic viruses and related human cancers has advanced rapidly in the past decade. Most articles, however, focus on a specific oncogenic virus and cancer. There is consequently a need for a comprehensive, up-to-date monograph that offers broad and integrated knowledge. Viruses and Human Cancer From Basic Science to Clinical Prevention is designed to meet this need by providing an advanced overview on the basic and clinical aspects of oncogenic viruses and the human cancers that they cause. Virology, virus-induced inflammation and tissue injuries, oncogenic mechanisms, epidemiology, and current and emerging preventive and therapeutic strategies are all discussed in detail. In addition, the book covers the individual aspects of seven oncogenic viruses, i.e., hepatitis B virus, hepatitis C virus, human papilloma virus, Epstein-Barr virus, human T-cell lymphotropic virus, Kaposi sarcoma-associated herpes virus, and Merkel cell polyomavirus, and the related human cancers. The susceptibility of high-risk hosts such as transplantation recipients is also addressed, and new vaccine developments are described